Physician profile
Scott C Leverage
NPI 1700064995
$9,577.02
in general payments reported to CMS, 2019-2025
40 companies · $2,098 in 2025
The $2,098 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $687 · 2021: $731 · 2022: $959 · 2023: $1,987 · 2024: $2,583 · 2025: $2,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,623 · Education: $45.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,622.91 |
| Education | $45.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,729.97 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,492.77 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Qol Medical, LLC | $722.04 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $613.03 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $597.03 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Genzyme Corporation | $408.36 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $398.17 | 2022-2025 | Dupixent |
| Pfizer INC. | $346.30 | 2019-2025 | |
| Daiichi Sankyo INC. | $341.65 | 2019-2025 | Injectafer |
| Ardelyx, INC. | $335.28 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $309.78 | 2023-2025 | Omvoh |
| Madrigal Pharmaceuticals | $288.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $244.35 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $214.05 | 2019-2025 | |
| Organon LLC | $168.11 | 2022-2025 | Renflexis, Hadlima |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $160.23 | 2020-2023 | Amjevita, Avsola |
| Braintree Laboratories, INC. | $151.94 | 2020-2025 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $106.87 | 2023-2024 | Voquezna |
| Celltrion USA INC. | $95.67 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Medtronic, INC. | $95.61 | 2021-2025 | Interstim |
| Ironwood Pharmaceuticals, INC | $87.52 | 2019-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $80.55 | 2019-2025 | Rebyota |
| Merck Sharp & Dohme LLC | $76.16 | 2022-2024 | Dificid |
| Redhill Biopharma INC. | $66.20 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Nestle Healthcare Nutrition INC. | $64.82 | 2021-2023 | |
| Boston Scientific Corporation | $58.63 | 2019-2021 | |
| Pharmacosmos Therapeutics INC. | $57.00 | 2024-2025 | Monoferric |
| Ucb, INC. | $48.25 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $32.67 | 2024 | |
| Allergan, INC. | $29.55 | 2020 | |
| Axonics, INC. | $21.93 | 2024 | Axonics |
| Shire North American Group INC | $20.75 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $17.50 | 2025 | Iqirvo |
| Ethicon US, LLC | $16.56 | 2025 | Linx Reflux Management System |
| Shionogi INC | $15.23 | 2020 | |
| Aimmune Therapeutics, INC. | $13.96 | 2024 | |
| Echosens North America, INC. | $13.23 | 2024 | Fibroscan |
| Evoke Pharma, INC. | $12.73 | 2023 | Gimoti |
| Alfasigma USA, INC. | $12.54 | 2020 | |
| Dova Pharmaceuticals | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Leverage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.